|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Neurology (S.E., A.R., C.K., I.W.H., A.F.) and Neuropaediatrics (G.K., O.D.), University of Münster, Germany.
* To whom correspondence should be addressed. E-mail: everss{at}uni-muenster.de.
Abstract-- The authors conducted a double-blind, placebo-controlled, crossover study to investigate the efficacy of oral zolmitriptan in the treatment of migraine in children and adolescents. Patients (n = 32) received placebo, zolmitriptan 2.5 mg, and ibuprofen 200 to 400 mg to treat three consecutive migraine attacks. Pain relief rates after 2 hours were 28% for placebo, 62% for zolmitriptan, and 69% for ibuprofen (p < 0.05). Both drugs are well tolerated with only mild side effects.
This article has been cited by other articles:
![]() |
D. H. Kornblau TREATMENT OF CHILDHOOD MIGRAINE ATTACKS WITH ORAL ZOLMITRIPTAN AND IBUPROFEN Neurology, April 24, 2007; 68(17): 1441 - 1441. [Full Text] [PDF] |
||||
![]() |
T. Tucker A Practical Approach to Headache Treatment Journal of Pharmacy Practice, April 1, 2007; 20(2): 123 - 136. [Abstract] [PDF] |
||||
![]() |
D. W. Lewis Pediatric Migraine Pediatr. Rev., February 1, 2007; 28(2): 43 - 53. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |